Novartis Signs Up to $1.8B Licensing Deal with UNP for Cardiovascular Peptide Therapeutics
Novartis has signed a research partnership and licensing agreement with Unnatural Products valued at up to $1.8 billion to develop macrocyclic peptide therapeutics targeting cardiovascular diseases using AI-driven drug discovery.